Ethylenecarbodiimide-treated splenocytes carrying male CD4 epitopes confer histocompatibility Y chromosome antigen transplant protection by inhibiting CD154 upregulation.
In humans and certain strains of laboratory mice, male tissue is recognized as nonself and destroyed by the female immune system via recognition of histocompatibility Y chromosome Ag (Hya). Male tissue destruction is thought to be accomplished by CTLs in a helper-dependent manner. We show that graft protection induced with the immunodominant Hya-encoded CD4 epitope (Dby) attached to female splenic leukocytes (Dby-SPs) with the chemical cross-linker ethylenecarbodiimide significantly, and often indefinitely, prolongs the survival of male skin graft transplants in an Ag-specific manner. In contrast, treatments with the Hya CD8 epitopes (Uty-/Smcy-SPs) failed to prolong graft survival. Dby-SP-tolerized CD4(+) T cells fail to proliferate, secrete IFN-gamma, or effectively prime a CD8 response in recipients of male grafts. Ag-coupled splenocyte treatment is associated with defective CD40-CD40L interactions as demonstrated by the observation that CD4 cells from treated animals exhibit a defect in CD40L upregulation following in vitro Ag challenge. Furthermore, treatment with an agonistic anti-CD40 Ab at the time of transplantation abrogates protection from graft rejection. Interestingly, anti-CD40 treatment completely restores the function of Dby-specific CD4 cells but not Uty- or Smcy-specific CD8 cells.
Martin
Aaron J
AJ
Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
McCarthy
Derrick
D
Waltenbaugh
Carl
C
Goings
Gwen
G
Luo
Xunrong
X
Miller
Stephen D
SD
D000595:Amino Acid Sequence; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D023201:CD40 Ligand / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000502:physiology; D002234:Carbodiimides / Q000276:immunology* / Q000494:pharmacology; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D006085:Graft Survival / Q000276:immunology; D006182:H-Y Antigen / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D016056:Immunodominant Epitopes / Q000008:administration & dosage / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D012727:Sex Characteristics; D013154:Spleen / Q000166:cytology / Q000276:immunology* / Q000637:transplantation; D015854:Up-Regulation / Q000276:immunology*; D014998:Y Chromosome / Q000276:immunology*
D002234:Carbodiimides; D018984:Epitopes, T-Lymphocyte; D006182:H-Y Antigen; D000949:Histocompatibility Antigens Class II; D016056:Immunodominant Epitopes; D023201:CD40 Ligand